Harry H. Yoon, MD, MHS | Authors

Articles

HER2 in Esophagogastric Adenocarcinoma

October 24, 2013

Determination of HER2 status has become an important part of the workup of patients with advanced esophagogastric cancer, given recent data from a phase III trial (ToGA) indicating that trastuzumab, an anti-HER2 monoclonal antibody, prolongs survival in these patients.